Australia markets open in 2 hours 50 minutes

SWK Holdings Corporation (SWKH)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
19.09-0.01 (-0.05%)
As of 01:49PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close19.10
Open19.05
Bid18.75 x 800
Ask19.28 x 900
Day's range18.75 - 19.14
52-week range13.28 - 20.49
Volume1,859
Avg. volume16,748
Market cap244.546M
Beta (5Y monthly)0.27
PE ratio (TTM)10.08
EPS (TTM)1.89
Earnings date30 Mar 2022 - 04 Apr 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est36.00
  • PR Newswire

    Enteris BioPharma Launches Enhanced Website Showcasing Full Suite of Bench to Market™ Services

    Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced today the launch of its newly enhanced corporate website encapsulating the company's full suite of Bench to Market™ services and its position as the preferred partner for the development and manufacture of oral BCS-III and BCS-IV drug products, including oral peptides, peptidomimeti

  • PR Newswire

    Special Committee Concludes Review of Non-Binding Proposal from Carlson Capital

    SWK Holdings Corporation (Nasdaq: SWKH) (the "Company" or "SWK") today announced that the special committee of the Company's board of directors (the "Special Committee") has concluded its investigation of the non-binding proposal received from funds managed by Carlson Capital, L.P. ("Carlson Capital") to acquire all shares of SWK not already owned by Carlson Capital.

  • PR Newswire

    Enteris BioPharma Highlights 2021 Achievements and 2022 Outlook

    Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), provided a review of its 2021 business achievements and development activities as the company anticipates growth opportunities during 2022 involving its industry-leading Peptelligence® and ProPerma® oral peptide and small molecule delivery technologies, and extensive pharmaceutical expertise.